Main content

Date created: | Last Updated:

: DOI | ARK

Creating DOI. Please wait...

Create DOI

Category: Project

Description: This first-in-human randomized clinical trial at Oslo University Hospital, Norway on patients with tuberculosis shows that the vaccine H56:I31 developed by Statens Serum Institut is safe and immunogenic during active tuberculosis disease and could serve as host-directed-therapy to improve prognosis and combat the tuberculosis pandemic

Wiki

Add important information, links, or images here to describe your project.

Files

Loading files...

Citation

Recent Activity

Loading logs...